Is CNST or RYLD a better dividend investment in 2026?

CNST currently yields 5.88% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: RYLD offers higher current income.

What is the dividend yield difference between CNST and RYLD?

CNST has a forward dividend yield of 5.88% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 6.26 percentage points.

Home › Compare › CNST vs RYLD

CNST vs RYLD: Dividend Comparison 2026

CNST yields 5.88% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 RYLD wins by $15.0K in total portfolio value

INVESTMENT

TIME HORIZON10 years

CNST

● Live price

5.88%

Share price

$33.99

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$29.5K

Annual income

$856.30

Full CNST calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — CNST vs RYLD

📍 RYLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CNST	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CNST + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CNST pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNST

Annual income on $10K today (after 15% tax)

$500.15/yr

After 10yr DRIP, annual income (after tax)

$727.85/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, RYLD beats the other by $1,471.39/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNST + RYLD for your $10,000?

CNST: 50%RYLD: 50%

100% RYLD50/50100% CNST

Portfolio after 10yr

$37.0K

Annual income

$1,721.82/yr

Blended yield

4.65%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on CNST right now

CNST

Analyst Ratings

Buy

Hold

Consensus: Buy

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNST buys

RYLD buys

No recent congressional trades found for CNST or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCNSTRYLD

Forward yield	5.88%	12.14% ✓
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$29.5K	$44.5K ✓
Annual income after 10y	$856.30	$2,587.35 ✓
Total dividends collected	$7.3K	$18.8K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: CNST vs RYLD ($10,000, DRIP)

Year	CNST Portfolio	CNST Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$11,288	$588.41	$11,914	$1,213.65	$626.00 → RYLD
2	$12,699	$620.77	$14,099	$1,351.30	$1.4K → RYLD
3	$14,241	$652.67	$16,580	$1,494.55	$2.3K → RYLD
4	$15,922	$684.02	$19,384	$1,642.61	$3.5K → RYLD
5	$17,751	$714.72	$22,535	$1,794.70	$4.8K → RYLD
6	$19,738	$744.71	$26,063	$1,950.00	$6.3K → RYLD
7	$21,894	$773.91	$29,995	$2,107.69	$8.1K → RYLD
8	$24,229	$802.26	$34,361	$2,266.99	$10.1K → RYLD
9	$26,755	$829.74	$39,194	$2,427.12	$12.4K → RYLD
10	$29,484	$856.30	$44,525	$2,587.35	$15.0K → RYLD

CNST vs RYLD: Complete Analysis 2026

CNST — Stock

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Full CNST Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this CNST vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNST vs SCHD CNST vs JEPI CNST vs O CNST vs KO CNST vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.